Reliance Life Sciences (RLS) and its fledgling subsidiary Reliance Pharmaceuticals Ltd (RPL) are looking at options, including roping in a strategic partner or an outright acquisition. The company is reported to be scouting for a potential acquisition in the US, an industry source told Business Line.
RLS had picked up 74 per cent equity in the UK-based biotech firm GeneMedix earlier this year. And this was followed up with RLS partnering with the US-based global investment management firm MPM Capital LP. The partnership envisaged RLS becoming a strategic partner in MPM Capital's newest fund, MPM BioVentures IV, with a corpus of $650 million.
(Source: Business Line)
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment